WHAT SHE SAID RADIO (SIRIUSXM)
There are still far too many myths and misconceptions surrounding medical cannabis. On Tuesday, Dr. Catherine Jacobson, the Director of Clinical Research at Tilray, appeared on What She Said Radio to debunk those myths and answer some frequently asked questions.
AUSTRALIAN BROADCASTING CORPORATION
The largest clinical trial of its kind, testing medicinal cannabis to treat chemotherapy patients suffering from nausea, has been announced by New South Wales Premier Mike Baird. About 330 patients are expected to take part in the clinical trial which will use a cannabis-derived tablet manufactured by Canadian company Tilray.
SYDNEY MORNING HERALD
A Canadian pharmaceutical company, Tilray, will supply the trial with specially-prepared tablets that contain marijuana extracts that maximise the drug's anti-nausea properties and minimise its psychoactive effects.
VANCOUVER SUN
A B.C. company licensed by Health Canada could be involved in the first Canadian trial of CBD oil and epilepsy in adults. Nanaimo-based Tilray will provide CBD oil capsules to a team working with the Ontario Brain Institute.
CAPITAL NEW YORK
Mount Sinai Health System is proposing to work with Tilray, a British Columbia medical marijuana company founded in 2013, to operate a clinical trial that would test the effectiveness of certain strains of the drug on severe forms of epilepsy.
THE GLOBE AND MAIL
Tilray announced Thursday it has teamed up with researchers at the University of British Columbia’s Okanagan campus to conduct the first clinical trial in Canada to test the impact of medicinal marijuana on PTSD sufferers.
BUSINESSWIRE
Pending regulatory approvals, the UBC-Tilray study is poised to be one of the first in the world to run a large-scale clinical trial examining medical cannabis as a treatment for a mental health disorder.
VANCOUVER SUN
A B.C. medical marijuana producer is seeking approval from Health Canada to sponsor the first study in Canada on the safety and effectiveness of cannabis for post-traumatic stress disorder (PTSD) among sexual assault victims, military veterans and first responder personnel.
